NCT06440525 - A Study of RSLV-132 in Females With Sjögren's Disease | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

March 1, 2027

Conditions

Primary Sjögren Syndrome

Interventions

DRUG

RSLV-132

Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)

DRUG

Placebo

0.9% sodium chloride solution

Trial Locations (24)

16635

RECRUITING

Altoona Center for Clinical Research, Duncansville

28204

RECRUITING

Joint and Muscle Research Institute, Charlotte

28208

RECRUITING

Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte

28277

RECRUITING

Onsite Clinical Solutions, Salisbury

33014

RECRUITING

Life Medical Research, Miami Gardens

33024

RECRUITING

Evolution Research Center, Hialeah

RECRUITING

GNP Research, Hollywood

33140

RECRUITING

Resolve Clinical Site, Miami

33467

RECRUITING

Resolve Clinical Site, Boynton Beach

34994

RECRUITING

Resolve Clinical Site, Boca Raton

37203

RECRUITING

Resolve Clinical Site, Nashville

52242

RECRUITING

University of Iowa, Iowa City

60607

RECRUITING

Resolve Clinical Site, Chicago

75069

RECRUITING

Resolve Clinical Site, McKinney

77089

RECRUITING

Accurate Clinical Research, Richmond

77449

RECRUITING

Resolve Clinical Site, Katy

78215

RECRUITING

Resolve Clinical Site, San Antonio

78757

RECRUITING

Resolve Clinical Site, Austin

84119

RECRUITING

Metrodora Institute, Salt Lake City

87106

RECRUITING

Resolve Clinical Site, Albuquerque

91910

RECRUITING

Resolve Clinical Site, Chula Vista

92780

RECRUITING

Resolve Clinical Site, Tustin

99204

RECRUITING

Arthritis Northwest, Spokane

02111-1817

RECRUITING

Tufts College, Boston